MedCap Q3 Adjusted EBITA Rises 30%; Sales Increase 13%
MedCap reported Q3 net sales growth of 13%, including 5% organic growth. All business areas grew; Specialty Pharma benefited from the prior XGX acquisition and higher non-recurring unlicensed pharma sales.